# A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

Source: https://onco.cc/trials/nct06246643/  
OnCo record `nct06246643` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Regorafenib in advanced solid tumours, run by Bayer, active and no longer recruiting.

## Summary

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies is a phase 2 interventional study registered as NCT06246643 by Bayer, with 13 participants enrolled, started 2024-01-24 and due to reach its primary completion in 2028-04-27. Interventions recorded: Regorafenib (Stivarga, BAY73-4506).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06246643
- Phase: 2
- Setting: A Single Arm, Open-label, Multicenter Phase 2 Study of Regorafenib in Participants Who Have Been Treated in a Previous Bayer-sponsored Regorafenib Study (Monotherapy or Combination Treatment) That Has Reached the Primary Completion Endpoint or the Main Data Analysis or Has Been Stopped Prematurely.
- Sponsor: Bayer
- Enrolled: 13

## Sources

- ClinicalTrials.gov NCT06246643: https://clinicaltrials.gov/study/NCT06246643

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Regorafenib](https://onco.cc/drugs/regorafenib/)
- companies: [Bayer](https://onco.cc/companies/bayer/)

---
JSON: https://onco.cc/api/v1/entities/nct06246643.json